GRIS-PEG by Bausch + Lomb. Approved for the following ringworm infections. First approved in 1975.
Drug data last refreshed 4h ago · AI intelligence enriched 3d ago
GRIS-PEG is an oral tablet formulation of griseofulvin, a fungistatic antifungal agent approved in 1975 for treating ringworm infections caused by Microsporum, Epidermophyton, and Trichophyton species. The drug works by depositing in keratin precursor cells and binding tightly to new keratin, making it highly resistant to fungal invasion. GRIS-PEG is a microcrystalline formulation of this established antifungal.
As LOE approaches with moderate competitive pressure (score: 30), commercial teams are likely consolidating or transitioning resources to newer antifungal portfolios.
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Working on GRIS-PEG offers limited career growth due to zero linked job openings and approaching loss of exclusivity; roles are primarily defensive/maintenance-focused rather than growth-oriented. This product is best suited for early-career professionals seeking mature market experience or interim assignments before moving to growth-stage franchises.
Worked on GRIS-PEG at Bausch + Lomb? Share your interview experience or compensation data (+7 days Pro)
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.